Loading…

IncyteINCYCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biopharma known for Jakafi/Jakavi (blood-cancer drug) and Opzelura for vitiligo/eczema, with an oncology pipeline.

Momentum strong 68
Mkt cap
$24.0B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$214M
20-day average traded
Fwd P/E
15.1×
forward earnings
ROIC−WACC
+21.4 pp
WACC 9.0%
Hurdle
+0 pp
Req g minus delivered
Next earnings
83 days
9 Feb 2027
Close · USD$117.80
1D-1.1%
1W-3.7%
1M+1.0%
3M-7.4%
6M+21.3%
YTD+19.3%
1Y+13.1%
ATR %3.2%
Beta0.46
52w lowhigh11.2% off high

What Incyte does

Biopharma known for Jakafi/Jakavi (blood-cancer drug) and Opzelura for vitiligo/eczema, with an oncology pipeline.

Sells Jakafi itself in the US, while Novartis sells the same drug as Jakavi elsewhere and pays Incyte royalties; royalties also come from Eli Lilly's Olumiant, a related JAK drug. Jakafi has carried the company for years, and Opzelura, a skin cream Incyte sells itself, is its second major product.

Products and services

  • Jakafi/Jakavi (myelofibrosis, GvHD)
  • Opzelura (vitiligo/eczema)
  • Oncology pipeline

Customers

  • Hematologists/oncologists
  • Dermatologists
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Hematology/oncology and dermatology

What could go right

  • Opzelura growth in dermatology
  • Jakafi/Jakavi international royalties (with Novartis)

What could go wrong

  • Eventual Jakafi patent expiry
  • Pipeline dependence for post-Jakafi growth

Moat: narrow (IP / patents, installed base). First-to-market JAK-inhibitor franchise with an entrenched hematology-oncology prescriber base.

Headquarters: Wilmington, Delaware, United States · Founded: 1991 · Employees: 2,844

Named competitors

Incyte at a glance

Size Incyte (INCY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $24.0B, the 441st largest of 3,085 United States companies the cockpit tracks. Shares closed at $117.80 on 18 Nov 2026.

Performance Over six months the shares gained 21.3%, against +7.6% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 24.9% over the last twelve months (peer median +29.3%); the operating margin is 11.7% (peer median 22.7%).

Valuation It trades at 15.1× forward earnings against a peer median of 22.4× (6th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 21.4 points above its cost of capital (9.0% WACC).

Short interest Short interest is 5.2% of the free float (30 Oct 2026).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026INCY 121Peer median 107
Six months, rebased to 100: Incyte against the median of its 20 peers (local-currency closes).

Incyte financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$6.01B$5.14B$4.24B$3.70B$3.39B
Revenue growth—+21%+15%+9%—
Gross profit$5.50B$4.70B$3.86B$3.38B$3.14B
EBITDA$799M$1.44B$169M$734M$667M
Net income$403M$1.29B$32.6M$598M$341M
Free cash flow$685M$1.35B$249M$464M$892M
Capital expenditure$65.1M$83.9M$100M$47.5M$77.8M
Total debt$37.4M$54.9M$60.3M$52.6M$55.6M

Quarterly statements and history in the cockpit →

Incyte competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+10%+20%VTRS3692SIGINSMROIVALNY1801TORNTPHARMDIVISLAB456845034507ASNDEXELZTSSOBIJAZZORNAVBIIB6446INCY6-month return →1-month return →
Up and to the right = strong over both horizons. Incyte is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%20×40×60×VTRS3692SIGALNY1801TORNTPHARMDIVISLAB456845034507ASNDJAZZ6446INCYRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Incyte is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%VTRS3692SIGALNY1801TORNTPHARMDIVISLAB45034507ASND6446INCYGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Incyte is the large dot.

Incyte competitors and peer comparison

Head to head with its named competitors (INCY vs BMY vs ABBV vs NOVN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Incyte INCY$24.0B+21%+25%12%15.1×14.2%
Bristol Myers Squibb BMY$122B+3%+4%33%9.2×-13.1%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%

How Incyte compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Incyte against its 20 peers (data as of 18 Nov 2026)
MeasureINCYPeer medianRank in peer set
1-month return+1.0%+6.5%6th lowest of 21
6-month return+21.3%+7.6%7th highest of 21
Distance from 52-week high-11.2%-9.1%10th lowest of 21
Revenue growth (TTM)+24.9%+29.3%10th lowest of 21
Operating margin11.7%22.7%5th lowest of 21
Forward P/E15.1×22.4×6th cheapest of 19
Growth the price implies (Req g, 7 yrs)14.2%7.7%6th most demanding of 19
Growth delivered (Del g)+14.0%+12.1%8th highest of 19
Hurdle (Req g minus delivered)+0.2 pp-13.0 pp6th most demanding of 19
ROIC minus cost of capital+21.4 pp+7.2 pp6th highest of 21
EV / EBITDA25.3×16.4×7th most expensive of 19
Net debt / EBITDA-4.8×0.1×3rd least indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Incyte INCYUnited States$24.0B+21%+25%12%15.1×14.2%+14.0%
Viatris VTRSUnited States$23.3B+23%+5%11%7.5×11.2%+3.7%
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%38.4×28.9%+26.1%
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%70.2×37.6%+11.3%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Shionogi & 4507.TJapan$17.6B+3%+46%29%11.8×0.2%+11.0%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%28.0×19.2%+152.4%
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%

Questions

Who are Incyte's main competitors?
Named competitors: Bristol Myers Squibb (BMY), AbbVie (ABBV), Novartis (NOVN.SW), Pfizer (PFE). The cockpit's measured peer set (industry) also includes Viatris (VTRS), Hansoh Pharma (3692.HK), Sigma Healthcare (SIG.AX), Insmed (INSM), Roivant Sciences (ROIV), Alnylam Pharmaceuticals (ALNY).
Is Incyte expensive compared with its peers?
On forward p/e it trades at 15.1× against a peer median of 22.4×, 6th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Incyte stock performed?
Over six months to 18 Nov 2026 the shares returned +21.3% against +7.6% for the median peer; over one year +13.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.